Begin Main Content Area

 Content Editor ‭[2]‬

Although the Capitol Complex is open to the public the Department of State is not open for visitors to enter NOB offices. Those constituents who wish to drop of materials for the Bureau of Corporations and Charitable Organizations or the Bureau of Elections should be advised to utilize the drop box across the street at the entrance of the Keystone Complex. Those with questions can be provided with the following phone number: 717-783-3945 and their call will be forwarded to the appropriate agency.

Bureau of Professional and Occupational Affairs staff are continuing to process applications as quickly as possible during this emergency. In order to increase the number of health care providers to respond to the COVID-19 emergency, the Governor has suspended certain licensing provisions. Due to the public health risk surrounding the Coronavirus, we are currently unable to accept walk-in customers and phone calls. For all inquiries, please utilize the email addresses found on the Board Contact Information webpage.

The processing of licenses and permits for health care practitioners continues to be a priority. Please refer to www.pals.pa.gov/verify to check the status of a license or permit.

For more details visit:

 

​COVID-19 Public Health Emergency Applications and Forms

Application for Reactivation of a Pharmacist License that has been Expired or Inactive for Less Than 4 Years (PDF)

Application for a Temporary Pharmacist License for Pharmacists Licensed In Other U.S. States (PDF)

Request to Compound under the Food and Drug Administration's Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency (PDF)

 

Coronavirus Information


FDA - Temporary Policy Regarding Non-Standard PPE Practices for Sterile Compounding

Learn more about the coronavirus (COVID-19) outbreak.

Information for telemedicine during the coronavirus emergency. 

Message from DEA regarding COVID-19 (PDF)

Targeted Distribution of PPE

On April 8, 2020, Governor Wolf Signed an order to provide targeted distribution of COVID-19 PPE and supplies to hospitals. The order requires private, public and quasi-public health care providers and facilities submit current inventory quantities of PPE, pharmaceuticals and other medical resources to PEMA by April 16, 2020. The survey link can be accessed hereOpens In A New Window.

Additionally, a FAQ regarding this topic can be found here

Suggestions for Board of Pharmacy for Pharmacists:

In response to COVID-19 and potential shortages of medications that may be effective against the virus such as hydroxychloroquine, pharmacists should verify the patient is confirmed COVID-19 positive before dispensing. Patients established on therapy or utilizing the medication for other diagnoses (e.g. Lupus or Rheumatoid Arthritis) should be able to continue to access without diagnosis verification. Smaller quantities of hydroxychloroquine should be dispensed to COVID-19 patients when appropriate to prevent potential shortages.  


 

State Board of Pharmacy ​


The Bureau of Professional and Occupational Affairs (BPOA) received reports that a person pretending to be from the State Board of Pharmacy (Board) is calling licensees about the status of their license.  The scammer asks for credit card information.  Persons who give their credit card information may not only lose their money, but also can become a victim of identity theft.

Licensees are urged to avoid becoming a victim of credit card fraud or identity theft:

  • BPOA and/or Board will NOT call licensees asking for payment over the phone.

  • If you get a text message or call asking for your credit card information, hang up.

  • Do NOT give your personal or financial information over the phone.

  • If you feel that you are a victim of any type of scam, you should immediately notify your local or state police.

 

Announcement for Pharmacist License Applicants

 

At the June 28, 2018 Pennsylvania State Board of Pharmacy (Board) Meeting, the Board voted to waive the requirement that Pharm.D. graduates of schools of pharmacy accredited by the Accreditation Council for Pharmacy Education (ACPE) earn at least 500 intern hours outside of their academic program.  This means that the 1,500 intern hours required for licensure as a pharmacist may be earned through an ACPE-accredited school of pharmacy’s Pharm.D. program and these graduates are no longer required to earn 500 intern hours outside of the school’s academic program.


 

Electronic Prescribing of Controlled Substances FAQs (PDF)

 

United States Pharmacopoeia (USP) (Rev. 12/19)

At the October 22, 2019 Pennsylvania State Board of Pharmacy (Board) Meeting, the Board discussed issues related to USP’s decision to delay implementation of the revisions to chapters 795 and 797 pending resolution of appeals. The following decisions were approved by the Board and placed on record:

  1. The Board is enforcing USP 795 and 797 as currently written. Board Regulation Section 27.601 was finalized on June 22, 2019 and requires compliance with section 503a of the federal Food, Drug and Cosmetic Act, federal regulations promulgated thereunder and the current version of the USP chapters governing compounding.
  2. The Board is delaying the enforcement of USP 800 until the appeals of certain provisions of the revised USP 795 and 797 are resolved. While enforcement of USP 800 is being delayed, pharmacies should do their best to comply with the requirements of USP 800, including the sections related to the handling of hazardous medications, as these requirements will be enforced at some time in the future, dependent on resolution of the appeals of the revised USP 795 and 797.
  3. The Board voted to adopt the following position and will be amending its regulations to reflect this information:

    The definition of "compounding" does not include the unencumbered flavoring of conventionally manufactured medications provided that the flavors used are inert, tested and do not alter a medication’s concentration beyond USP’s accepted level of variance.

Note: Please refer to the following links for additional information on USP 800 and its scope (i.e. it would be applicable only when a practitioner is engaged in compounding):

https://www.usp.org/sites/default/files/usp/document/our-work/compounding/usp-800-context-for-implementation-fs.pdf

https://www.usp.org/sites/default/files/usp/document/our-work/compounding/faqs-usp-800.pdf

 

Please note that neither the Board/Commission, nor its staff or counsel, are permitted to provide legal advice or advisory opinions, including interpretations of the law or regulations, or any indication as to how the Board would vote on any given case or scenario.  You are invited to contact a private attorney or professional organization for advice or guidance.